2[1]Bain-Forster, Sleigh. Heparin and the activated partial thromboplastin time-A difference between the in-vitro and ex-vivo effects and implications for teh theapeutic range. Am J Clin Pathol, 1980,74: 668 ～ 772.
3[2]Turi DC, Peerschke EL. Sensitivity of the activated parial thromboplastin time reagents to coagulation factor deficiencies. Am J Clin Pathol, 1986,85:43～49.
4[3]Poller L. Standardization of the APTT test. Current statuts. Scand J Haematol, 1980,37(suppl 24) :49 ～ 63.
5[4]Basu D. A prospective study of the value of mormitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med, 1972,187:324～ 327.
6[5]Brand, Triplett. Laboratory monitoring heparin effect of reagents and instruments on the activated prtial thromboplastin time. Am J Clin Pathol, 1981,76: 530 ～ 537.
7[6]Zark, Shojannia. Comparitin of two APTT methods of moitoring heparin therapy. Am J Clin Pathlo, 1990,93:684 ～ 688.
8National Committee for Clinical Laboratory Standards. How to define and reference intervals in the clinical laboratory [ S ]. Wayne, PA : 2000, C282A2 NCCLS,24-25.
9Solberg HE,Stamm D.International Federation of Clinical Chemistry IFCC.IFCC recommendation-theory of reference values.Part 4.Control of analytical variation in the production,transfer and application of reference values[J].Clin Chim Acta,1991,202(1/2):S5.
10Fuentes-Arderiu X,Mas-Serra R,Aluma-Trullas A,et a1.Guideline for the production of multicentre physiological reference values using the Same measurement system.A proposal of the Catalan Association for Clinical Laboratory Sciences[J].Clin Chem Lab Med,2004,42(7):778.
